Int J Cancer. 1991 Sep 9;49(2):191-5.
The use of depot-medroxyprogesterone acetate (DMPA), a long-acting progestational contraceptive, in relation to risk of epithelial ovarian cancer was examined in a hospital-based case-control study conducted in Mexico and Thailand. Women with histologically confirmed epithelial ovarian cancer (n = 224) diagnosed between 1979 and 1988 were compared with hospital controls (n = 1,781) matched on age, hospital and year of interview. Overall, 9.8% of cases and 12.9% of controls had ever used DMPA. The relative-risk (RR) estimate in women who had ever used DMPA, controlling for the confounding effects of number of live births and oral contraceptive use, was 1.07 (95% CI 0.6, 1.8). No consistent patterns of increasing or decreasing risk were noted according to duration of use, time since first or most recent use or age at first use of DMPA. These results suggest that the risk of epithelial ovarian cancer is not altered by the use of DMPA.
在墨西哥和泰国开展的一项基于医院的病例对照研究中，对长效孕激素避孕针醋酸甲羟孕酮（DMPA）的使用与上皮性卵巢癌风险之间的关系进行了研究。将1979年至1988年间经组织学确诊为上皮性卵巢癌的女性（n = 224）与根据年龄、医院和访谈年份匹配的医院对照者（n = 1,781）进行比较。总体而言，9.8%的病例和12.9%的对照者曾使用过DMPA。在控制活产数和口服避孕药使用的混杂效应后，曾使用DMPA的女性的相对风险（RR）估计值为1.07（95%置信区间0.6，1.8）。根据DMPA的使用持续时间、首次或最近一次使用后的时间或首次使用时的年龄，未观察到风险增加或降低的一致模式。这些结果表明，使用DMPA不会改变上皮性卵巢癌的风险。
